Cannabis medicines are changing the way pain could be managed for millions of Australian and international patients who suffer with chronic pain everyday.
The TGA has recommended to physicians that opiates are now not to be a recommended prescription medicine for pain patients, we believe that cannabis may be a good 2nd line therapy for pain patients worldwide. We plan to run clinical studies to provide evidence to prove it.
We also believe that there are exciting developments to be made around the chemicals within the plant that could alleviate pain. Cymra Life Sciences is researching all compounds of the plant and testing in formulations to understand how they may work in synergy to improve inflammation and pain.
We are the only cannabis company in Australia, and one of a few worldwide, who are focusing on the genetic development and supply to cannabis cultivators.
Based on limited research, due to federal regulation, more effective strains can be developed quickly for pest and disease resistance, higher yields, specific compounds and agronomic benefits.
Our experiences in breeding and Tissue Culture in other industries allows us to accelerate quickly into this growing sector
We use tissue culture propagation methods to create unique high health cultivars free from pests & diseases for our cultivation partners.
Our products and clinical development plan are based on extracts which preserve the balance of the whole plant and target chronic and neuropathic pain.
Our team are world class leaders in pharmaceuticals, plant breeding, genetics, tissue culture and drug development
Understand our medical cannabis clinical trial, products, along with dosing and administration advice